|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Utility of serological markers in inflammatory bowel diseases: Gadget or magic?显示文摘为煽动性的肠疾病(IBD ) 的血清学标记的面板很快正在膨胀。尽管 anti-Saccharomyces 啤酒抗体(ASCA ) 和不正常的仙子细胞质的抗体(P-ANCA ) 仍然是的原子反 neutrophil 广泛地调查的大多数,试验性的数据的增加的数量在对各种各样的微生物引起的抗原指导的最新发现的抗体上是可得到的。对在当前的 IBD 诊断算法的各种各样的抗体的评价的角色由于他们的有限敏感经常是可疑的。相反,有疾病行为和显型的血清学标记的协会正在变得逐渐地生长得很好。越来越多的观察证实有 Crohn 在高乳头 ers 表示多重血清学标记的疾病的病人是更可能的有复杂的小肠疾病(例如苛评或穿孔) 并且没有,或与抗体的低乳头 ers,比那些在为外科的更高的风险。基于血清学反应创造同质的疾病亚群可以帮助开发更多的标准化治疗学的途径并且可以在 IBD 的 pathomechanism 的更好的理解帮助。进一步未来的临床的研究被需要在 IBD 建立 serologic 的临床的角色。 | Maria Papp Gary L Norman Istvan Altorjay Peter Laszlo Lakatos | 2007 | World Journal of Gastroenterology2007，13，14： | 24 |
| 2 | Immune dysfunction in cirrhosis显示文摘Innate and adaptive immune dysfunction,also referred to as cirrhosis-associated immune dysfunction syndrome,is a major component of cirrhosis,and plays a pivotal role in the pathogenesis of both the acute and chronic worsening of liver function.During the evolution of the disease,acute decompensation events associated with organ failure(s),so-called acute-on chronic liver failure,and chronic decompensation with progression of liver fibrosis and also development of disease specific complications,comprise distinct clinical entities with different immunopathology mechanisms.Enhanced bacterial translocation associated with systemic endotoxemia and increased occurrence of systemic bacterial infections have substantial impacts on both clinical situations.Acute and chronic exposure to bacteria and/or their products,however,can result in variable clinical consequences.The immune status of patients is not constant during the illness;consequently,alterations of the balance between pro-and anti-in-flammatory processes result in very different dynamic courses.In this review we give a detailed overview of acquired immune dysfunction and its consequences for cirrhosis.We demonstrate the substantial influence of inherited innate immune dysfunction on acute and chronic inflammatory processes in cirrhosis caused by the pre-existing acquired immune dysfunction with limited compensatory mechanisms.Moreover,we highlight the current facts and future perspectives of how the assessment of immune dysfunction can assist clinicians in everyday practical decision-making when establishing treatment and care strategies for the patients with end-stage liver disease.Early and efficient recognition of inappropriate performance of the immune system is essential for overcoming complications,delaying progression and reducing mortality. | Nora Sipeki Peter Antal-Szalmas Peter L Lakatos Maria Papp | 2014 | World Journal of Gastroenterology2014，20，10： | 10 |
| 3 | Presepsin teardown- pitfalls of biomarkers in the diagnosis and prognosis of bacterial infection in cirrhosis显示文摘AIM To evaluate the diagnostic and prognostic value of presepsin in cirrhosis-associated bacterial infections. METHODS Two hundred and sixteen patients with cirrhosis were enrolled. At admission, the presence of bacterial infections and level of plasma presepsin, serum C-reactive protein(CRP) and procalcitonin(PCT) were evaluated. Patients were followed for three months to assess the possible association between presepsin level and short-term mortality.RESULTS Present 34.7 of patients had bacterial infection. Presepsin levels were significantly higher in patients with infection than without(median, 1002 pg/m L vs 477 pg/m L, P < 0.001), increasing with the severity of infection [organ failure(OF): Yes vs No, 2358 pg/m L vs 710 pg/m L, P < 0.001]. Diagnostic accuracy of presepsin for severe infections was similar to PCT and superior to CRP(AUC-ROC: 0.85, 0.85 and 0.66, respectively, P = NS for presepsin vs PCT and P < 0.01 for presepsin vs CRP). At the optimal cut-off value of presepsin > 1206 pg/m L sensitivity, specificity, positive predictive values and negative predictive values were as follows: 87.5%, 74.5%, 61.8% and 92.7%. The accuracy of presepsin, however, decreased in advanced stage of the disease or in the presence of renal failure, most probably because of the significantly elevated presepsin levels in non-infected patients. 28-d mortality rate was higher among patients with > 1277 pg/m L compared to those with ≤ 1277 pg/m L(46.9% vs 11.6%, P < 0.001). In a binary logistic regression analysis, however, only PCT(OR = 1.81, 95%CI: 1.09-3.01, P = 0.022) but neither presepsin nor CRP were independent risk factor for 28-d mortality after adjusting with MELD score and leukocyte count.CONCLUSION Presepsin is a valuable new biomarker for defining severe infections in cirrhosis, proving same efficacy as PCT. However, it is not a useful marker of short-term mortality. | Maria Papp Tamas Tornai Zsuzsanna Vitalis Istvan Tornai David Tornai Tamas Dinya Andrea Sumegi Peter Antal-Szalmas | 2016 | World Journal of Gastroenterology2016，22，41： | 9 |
| 4 | Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis显示文摘AIM To assess the prevalence of a panel of serologic markers that reflect gut barrier dysfunction in a mixed cohort of pediatric and adult primary sclerosing cholangitis(PSC) patients.METHODS Sera of 67 PSC patients [median age(range): 32(5-79) years, concomitant IBD: 67% and cirrhosis: 20%] were assayed for the presence of antibodies against to F-actin(AAA Ig A/Ig G) and gliadin(AGA Ig A/Ig G)] and for serum level of intestinal fatty acid-binding protein(I-FABP) by ELISA. Markers of lipopolysaccharide(LPS) exposure [LPS binding protein(LBP)] and various antimicrobial antibodies [anti-OMP Plus Ig A and endotoxin core Ig A antibody(Endo CAb)] were also determined. Poor disease outcome was defined as orthotopic liver transplantation and/or liver-related death during the follow-up [median: 99(14-106) mo]. One hundred and fifty-three healthy subjects(HCONT) and 172 ulcerative colitis(UC) patients were the controls. RESULTS A total of 28.4%, 28.0%, 9% and 20.9% of PSC patients were positive for AAA Ig A, AAA Ig G, AGA Ig A and AGA Ig G, respectively. Frequencies of AAA Ig A and AAA Ig G(P < 0.001, for both) and AGA Ig G(P = 0.01, for both) but not AGA Ig A were significantly higher compared to both of the HCONT and the UC groups. In survival analysis, AAA Ig A-positivity was revealed as an independent predictor of poor disease outcome after adjusting either for the presence of cirrhosis [HR = 5.15(1.27-20.86), P = 0.022 or for the Mayo risk score(HR = 4.24(0.99-18.21), P = 0.052]. AAA Ig A-positivity was significantly associated with higher frequency of antimicrobial antibodies(P < 0.001 for Endo Cab Ig A and P = 0.012 for anti-OMP Plus Ig A) and higher level of the enterocyte damage marker(median I-FABP_(AAA Ig A pos vs neg): 365 vs 166 pg/m L, P = 0.011), but not with serum LBP level. CONCLUSION Presence of Ig A type AAA identified PSC patients with progressive disease. Moreover, it is associated with enhanced mucosal immune response to various microbial antigens and enterocyte damage further highlighting the importance of the gut-liver interaction in PSC. | Tamas Tornai Eszter Palyu Zsuzsanna Vitalis Istvan Tornai David Tornai Peter Antal-Szalmas Gary L Norman Zakera Shums Gabor Veres Antal Dezsofi Gabriella Par Alajos Par Peter Orosz Ferenc Szalay Peter Laszlo Lakatos Maria Papp | 2017 | World Journal of Gastroenterology2017，23，29： | 5 |
| 5 | NKX2-3 and IRGM variants are associated with diseasesu sceptibility to IBD in Eastern European patients显示文摘AIM: To investigate variants of immunity-related GT-Pase family M (IRGM) and NKX2-3 genes and genotype-phenotype in Eastern European patients with inflammatory bowel disease (IBD).METHODS: We analyzed 1707 Hungarian and Czech subjects with Crohn’s disease (CD) (n = 810, age: 37.1 ± 12.6 years, duration: 10.7 ± 8.4 years) and ulcerative colitis (UC) (n = 428, age: 43.7 ± 15.0 years, duration: 12.6 ± 9.9 years), as well as 469 healthy controls. IRGM rs13361189, NKX2-3 rs10883365 and ECM1 rs13294 polymorphisms were tested by LightCy-cler allele discrimination. Detailed clinical phenotypes were determined by reviewing the medical charts. RESULTS: NKX2-3 rs10883365 variant allele was as-sociated with increased risk for CD (P = 0.009, OR = 1.24, 95% CI = 1.06-1.48) and UC (P = 0.001, OR = 1.36, 95% CI = 1.13-1.63), whereas variant IRGM allele increased risk for CD (P = 0.029, OR = 1.36, 95% CI = 1.03-1.79). In contrast, ECM1 rs13294 was not associat-ed with either CD or UC. In CD, the variant IRGM allele was associated with a colon-only location (P = 0.02, OR = 1.62, 95% CI = 1.07-2.44), whereas in UC, the ECM1 variant was associated with cutaneous manifestations (P = 0.002, OR = 3.36, 95% CI = 1.48-7.63). Variant alleles did not predict resistance to steroids or azathio-prine, efficacy of infliximab, or need for surgery. CONCLUSION: NKX2-3 and IRGM are susceptibility locifor IBD in Eastern European patients. Further studies are needed to confirm the reported phenotype-genotype associations. | Nora Meggyesi Lajos S Kiss Magdalena Koszarska Martin Bortlik Dana Duricova Laszlo Lakatos Tamas Molnar Martin Lenicek Libor Vítek Istvan Altorjay Maria Papp Zsolt Tulassay Pal Miheller Janos Papp Attila Tordai Hajnalka Andrikovics Milan Lukas Peter Laszlo Lakatos | 2010 | World Journal of Gastroenterology2010，16，41： | 2 |
| 6 | High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis显示文摘 | Maria Papp Nora Sipeki Zsuzsanna Vitalis Tamas Tornai Istvan Altorjay Istvan Tornai Miklos Udvardy Kai Fechner Silvia Jacobsen Bianca Teegen Andrea Sumegi Gabor Veres Peter Laszlo Lakatos Janos Kappelmayer Peter Antal-Szalmas | 2013 | Journal of Hepatology2013，，： | 1 |
| 7 | Diagnostic and clinical significance of Crohn’s disease-specific anti-MZGP2 pancreatic antibodies by a novel ELISA显示文摘 | Polychronis Pavlidis Zakera Shums Andreas L. Koutsoumpas Jay Milo Maria Papp Takeji Uemurea Peter Lakatos Daniel S. Smyk Dimitrios P. Bogdanos Alastair Forbes Gary L. Norman | 2014 | Clinica Chimica Acta2014，，： | 1 |
| 8 | Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn?s disease, while smoking decreases the risk of colectomy in ulcerative colit显示文摘 | Tamas Szamosi Janos Banai Laszlo Lakatos Zsofia Czegledi Gyula David Ferenc Zsigmond Tunde Pandur Zsuzsanna Erdelyi Orsolya Gemela Maria Papp Janos Papp Peter Laszlo Lakatos | 2010 | European Journal of Gastroenterology & Hepatology2010，，7： | 1 |
| 9 | High prevalence of IgA class anti-neutrophil cytoplasmic antibodies (ANCA) is associated with increased risk of bacterial infection in patients with cirrhosis<!-- Doctopic: CIRR -->显示文摘 | Maria Papp Nora Sipeki Zsuzsanna Vitalis Tamas Tornai Istvan Altorjay Istvan Tornai Miklos Udvardy Kai Fechner Silvia Jacobsen Bianca Teegen Andrea Sumegi Gabor Veres Peter Laszlo Lakatos Janos Kappelmayer Peter Antal-Szalmas | 2013 | Journal of Hepatology2013，，： | 1 |
| 10 | Gap junctional uncoupling plays a trigger role in the antiarrhythmic effect of ischamemic preconditioning显示文摘 | Rita Papp Marton Gonczi Maria Kovacs | 2007 | Cardiovascular Research2007，74，3： | 1 |
| 11 | High‐sensitivity C‐reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn’s disease: A marker for patient classification?显示文摘 | Lajos Sandor Kiss Maria Papp Barbara Dorottya Lovasz Zsuzsanna Vegh Petra Anna Golovics Eszter Janka Eva Varga Miklos Szathmari Peter Laszlo Lakatos | 2011 | Inflamm Bowel Dis2011，，9： | 1 |
| 12 | Pancreatic Autoantibodies and Autoantibodies Against Goblet Cells in Pediatric Patients With Inflammatory Bowel Disease显示文摘 | Marta Kovacs Peter Laszlo Lakatos Maria Papp Silvia Jacobsen Eva Nemes Marianne Polgar Eniko Solyom Piroska Bodi Agnes Horvath Katalin Eszter Muller Kriszta Molnar Doloresz Szabo Aron Cseh Antal Dezsofi Andras Arato Gabor Veres | 2012 | Journal of Pediatric Gastroenterology and Nutrition2012，，4： | 1 |
| 13 | Prevalence, significance and predictive value of antiphospholipid antibodies in Crohn's disease显示文摘AIM: To assess the prevalence and stability of different antiphospholipid antibodies(APLAs) and their association with disease phenotype and progression in inflammatory bowel diseases(IBD) patients.METHODS: About 458 consecutive patients [Crohn's disease(CD): 271 and ulcerative colitis(UC): 187] were enrolled into a follow-up cohort study in a tertiary IBD referral center in Hungary. Detailed clinical phenotypes were determined at enrollment by reviewing the patients' medical charts. Disease activity, medical treatment and data about evolvement of complications or surgical interventions were determined prospectively during the follow-up. Disease course(development f complicated disease phenotype and need for surgery),occurrence of thrombotic events, actual state of diseaseactivity according to clinical, laboratory and endoscopic scores and accurate treatment regime were recorded during the follow-up,(median, 57.4 and 61.6 mo for CD and UC). Sera of IBD patients and 103 healthy controls(HC) were tested on individual anti-β2-Glycoprotein-I(anti-β2-GPI IgA/M/G), anti-cardiolipin(ACA IgA/M/G)and anti-phosphatidylserine/prothrombin(anti-PS/PT IgA/M/G) antibodies and also anti-Saccharomyces cerevisiae antibodies(ASCA IgA/G) by enzyme-linked immunosorbent assay(ELISA). In a subgroup of CD(n = 198) and UC patients(n = 103), obtaining consecutive samples over various arbitrary timepoints during the disease course, we evaluated the intraindividual stability of the APLA status. Additionally,we provide an overview of studies, performed so far, in which significance of APLAs in IBD were assessed.RESULTS: Patients with CD had significantly higher prevalence of both ACA(23.4%) and anti-PS/PT(20.4%) antibodies than UC(4.8%, p < 0.0001 and10.2%, p = 0.004) and HC(2.9%, p < 0.0001 and15.5%, p = NS). No difference was found for the prevalence of anti-β2-GPI between different groups(7.2%-9.7%). In CD, no association was found between APLA and ASCA status of the patients.Occurrence of anti-β2-GPI, ACA and anti-PS/PT was not different between the group of patients with active vs inactive disease state according to appropriate clinical, laboratory and endoscopic scores in CD as well as in UC patients. All subtypes of anti-β2-GPI and ACA IgM status were found to be very stable over time, in contrast ACA IgG and even more ACA IgA status showed significant intraindividual changes.Changes in antibody status were more remarkable in CD than UC(ACA IgA: 49.9% vs 23.3% and ACA IgG:21.2% vs 5.8%). Interestingly, 59.1% and 30.1% of CD patients who received anti-TNF therapy showed significant negative to positive changes in ACA IgA and IgG antibody status respectively. APLA status was not associated with the clinical phenotype at diagnosis or during follow-up, medical therapy, or thrombotic events and it was not associated with the probability of developing complicated disease phenotype or surgery in a Kaplan-Meier analysis.CONCLUSION: The present study demonstrated enhanced formation of APLAs in CD patients. However,presence of different APLAs were not associated with the clinical phenotype or disease course. | Nora Sipeki Laszlo Davida Eszter Palyu Istvan Altorjay Jolan Harsfalvi Peter Antal Szalmas Zoltan Szabo Gabor Veres Zakera Shums Gary L Norman Peter L Lakatos Maria Papp | 2015 | World Journal of Gastroenterology2015，21，22： | 1 |
| 14 | Anti-microbial antibodies in celiac disease:Trick or treat?显示文摘AIM:To determine the prevalence of a new set of anti-glycan and anti-outer membrane protein (anti-OMP) antibodies in a Hungarian cohort of adult Celiac disease (CD) patients.METHODS:190 consecutive CD patients [M/F:71/119, age:39.9 (SD:14.1) years], 100 healthy, and 48 gastrointestinal controls were tested for glycan anti-Saccharomyces cerevisiae (gASCA), anti-laminaribioside (ALCA), anti-chitobioside, anti-mannobioside, anti-OMP antibodies and major NOD2/CARD15 mutations. Thirty out of 82 CD patients enrolled at the time of diagnosis were re-evaluated for the same antibodies after longstanding gluten-free diet (GFD).RESULTS: 65.9% of the CD patients were positive for at least one of the tested antibodies at the time of the diagnosis. Except anti-OMP and ALCA, anti-microbial antibodies were exclusively seen in untreated CD; however, the overall sensitivity was low. Any glycan positivity (LR+:3.13;95% CI:2.08-4.73) was associated with an increased likelihood ratio for diagnosing CD. Significant correlation was found between the levels of anti-glycan and anti-endomysial or anti-transglutaminase antibodies. Anti-glycan positivity was lost after longstanding GFD. Anti-glycan antibody titers were associated with symptoms at presentation, but not the presence of NOD2/CARD15 mutations. Patients with severe malabsorption more frequently had multiple antibodies at diagnosis (P=0.019).CONCLUSION: The presence of anti-glycan antibodies in CD seems to be secondary to the impaired small bowel mucosa which can lead to increased antigen presentation. Furthermore, anti-glycan positivity may be considered an additional marker of CD and dietary adherence. | Maria Papp Ildiko Foldi Istvan Altorjay Eszter Palyu Miklos Udvardy Judit Tumpek Sandor Sipka Ilma Rita Korponay-Szabo Eva Nemes Gabor Veres Tamas Dinya Attila Tordai Hajnalka Andrikovics Gary L Norman Peter Laszlo Lakatos | 2009 | World Journal of Gastroenterology2009，15，31： | 0 |
| 15 | Location-based prediction model for Crohn’s disease regarding a novel serological marker,anti-chitinase 3-like 1 autoantibodies显示文摘BACKGROUND Defective neutrophil regulation in inflammatory bowel disease(IBD)is thought to play an important role in the onset or manifestation of IBD,as it could lead to damage of the intestinal mucosal barrier by the infiltration of neutrophils in the inflamed mucosa and the accumulation of pathogens.Like neutrophils in the context of innate immune responses,immunoglobulin A(IgA)as an acquired immune response partakes in the defense of the intestinal epithelium.Under normal conditions,IgA contributes to the elimination of microbes,but in connection with the loss of tolerance to chitinase 3-like 1(CHI3L1)in IBD,IgA could participate in CHI3L1-mediated improved adhesion and invasion of potentially pathogenic microorganisms.The tolerance brake to CHI3L1 and the occurrence of IgA autoantibodies to this particular target,the exact role and underlying mechanisms of CHI3L1 in the pathogenesis of IBD are still unclear.AIM To determine the predictive potential of Ig subtypes of a novel serological marker,anti-CHI3L1 autoantibodies(aCHI3L1)in determining the disease phenotype,therapeutic strategy and long-term disease course in a prospective referral cohort of adult IBD patients.METHODS Sera of 257 Crohn’s disease(CD)and 180 ulcerative colitis(UC)patients from a tertiary IBD referral center of Hungary(Division of Gastroenterology,Department of Internal Medicine,Faculty of Medicine,University of Debrecen)were assayed for IgG,IgA,and secretory IgA(sIgA)type aCHI3L1 by enzyme-linked immunosorbent assay using recombinant CHI3L1,along with 86 healthy controls(HCONT).RESULTS The IgA type was more prevalent in CD than in UC(29.2%vs 11.1%)or HCONT(2.83%;P<0.0001 for both).However,sIgA subtype aCHI3L1 positivity was higher in both CD and UC patients than in HCONT(39.3%and 32.8%vs 4.65%,respectively;P<0.0001).The presence of both IgA and sIgA aCHI3L1 antibodies was associated with colonic involvement(P<0.0001 and P=0.038,respectively)in patients with CD.Complicated disease behavior at sample procurement was associated with aCHI3L1 sIgA positivity(57.1%vs 36.0%,P=0.009).IgA type aCH3L1 was more prevalent in patients with frequent relapse during the disease course in the CD group(46.9%vs 25.7%,P=0.005).In a group of patients with concomitant presence of pure inflammatory luminal disease and colon involvement at the time of diagnosis,positivity for IgA or sIgA type aCH3L1 predicted faster progression towards a complicated disease course in time-dependent models.This association disappeared after merging subgroups of different disease locations.CONCLUSION CHI3L1 is a novel neutrophil autoantigenic target in IBD.The consideration of antibody classes along with location-based prediction may transform the future of serology in IBD. | Nora Sipeki Patricia Julianna Kovats Claudia Deutschmann Peter Schierack Dirk Roggenbuck Maria Papp | 2023 | World Journal of Gastroenterology2023，29，42： | 0 |
| 16 | Serological biomarkers for management of primary sclerosing cholangitis显示文摘Clinical manifestations and progression of primary sclerosing cholangitis(PSC)are heterogeneous,and its pathogenesis is poorly understood.The importance of gut-liver interactions in the pathogenesis has been clinically confirmed and highlighted in different theories.Recent advances regarding biomarkers of biliarygut crosstalk may help to identify clinically relevant PSC subgroups assisting everyday clinical work-up(e.g.,diagnosis,disease stratification,or surveillance)and the exploration of potential therapeutic targets.Alkaline phosphatase produced by the biliary epithelium is consistently associated with prognosis.However,its level shows natural fluctuation limiting its use in individual patients.Inflammatory,cell activation,and tissue remodeling markers have been reported to predict clinical outcome.Elevated immunoglobulin(Ig)G4 level is associated with a shorter transplantation-free survival.IgG type atypical perinuclear anti-neutrophil cytoplasmic antibodies(P-ANCAs)are non-specific markers of various autoimmune liver diseases and may reflect an abnormal B-cell response to gut microbial antigens.IgG type atypical P-ANCA identifies PSC patients with particular clinical and genetic(for human leukocyte antigens)characteristics.The presence of IgA type anti-F-actin antibody(AAA)may predict a progressive disease course,and it is associated with enhanced mucosal immune response to various microbial antigens and enterocyte damage.IgA type anti-glycoprotein 2(GP2)antibodies identify patients with a severe disease phenotype and poor survival due to enhanced fibrogenesis or development of cholangiocarcinoma.Elevated soluble vascular adhesion protein-1(sVAP-1)level is associated with adverse disease outcomes in PSC.High sVAP-1 levels correlate with mucosal addressin cell adhesion molecule-1(MAdCAM-1)expression in the liver that contributes to gut activated T-cell homing to the hepatobiliary tract.In the present paper,we review the evidence on these possible serological markers that could potentially help address the unmet clinical needs in PSC. | David Tornai Peter Laszlo Ven Peter Laszlo Lakatos Maria Papp | 2022 | World Journal of Gastroenterology2022，28，21： | 0 |
| 17 | Fungal diversity notes 1277-1386:taxonomic and phylogenetic contributions to fungal taxa显示文摘This is the twelfth contribution to the Fungal Diversity Notes series on fungal taxonomy,based on materials collected from many countries which were examined and described using the methods of morphology,anatomy,and strain culture,combined with DNA sequence analyses.110 taxa are described and illustrated,including five new genera,92 new species,eight new combinations and other taxonomic contributions(one new sequenced species,one new host and three new records)which are accommodated in 40 families and 1 incertae sedis in Dothideomycetes.The new genera are Amyloceraceomyces,Catenuliconidia,Hansenopezia,Ionopezia and Magnopulchromyces.The new species are Amyloceraceomyces angustisporus,Amylocorticium ellipsosporum,Arthrinium sorghi,Catenuliconidia uniseptata,Clavulina sphaeropedunculata,Colletotrichum parthenocissicola,Coniothyrium triseptatum,Cortinarius indorusseus,C.paurigarhwalensis,C.sinensis,C.subsanguineus,C.xiaojinensis,Diaporthe pimpinel-lae,Dictyosporella guizhouensis,Diplodia torilicola,Fuscoporia marquesiana,F.semiarida,Hansenopezia decora,Helicoarcta-tus thailandicus,Hirsutella hongheensis,Humidicutis brunneovinacea,Lentaria gossypina,L.variabilis,Lycoperdon lahorense,L.pseudocurtisii,Magnopulchromyces scorpiophorus,Moelleriella gracilispora,Neodevriesia manglicola,Neodidymelliopsis salvia,N.urticae,Neoroussoella magnoliae,Neottiella gigaspora,Ophiosphaerella chiangraiensis,Phaeotremella yunnanensis,Podosphaera yulii,Rigidoporus juniperinus,Rhodofomitopsis pseudofeei,Russula benghalensis,Scleroramularia vermispora,Scytinopogon minisporus,Sporormurispora paulsenii,Thaxteriellopsis obliqus,Tomentella asiae-orientalis,T.atrobadia,T.atrocastanea,T.aureomarginata,T.brevis,T.brunneoflava,T.brunneogrisea,T.capitatocystidiata,T.changbaiensis,T.citri-nocystidiata,T.coffeae,T.conclusa,T.cystidiata,T.dimidiata,T.duplexa,T.efibulata,T.efibulis,T.farinosa,T.flavidobadia,T.fuscocrustosa,T.fuscofarinosa,T.fuscogranulosa,T.fuscopelliculosa,T.globospora,T.gloeocystidiata,T.griseocastanea,T.griseofusca,T.griseomarginata,T.inconspicua,T.incrustata,T.interrupta,T.liaoningensis,T.longiaculeifera,T.longiechinuli,T.megaspora,T.olivacea,T.olivaceobrunnea,T.pallidobrunnea,T.pallidomarginata,T.parvispora,T.pertenuis,T.qingyuanensis,T.segregata,T.separata,T.stipitata,T.storea,Trichoderma ceratophylletum,Tyromyces minutulus,Umbelopsis heterosporus and Xylolentia reniformis.The new combinations are Antrodiella descendena,Chloridium macrocladum,Hansenopezia retrocurvata,Rhodofomitopsis monomitica,Rh.oleracea,Fuscoporia licnoides,F.scruposa and Ionopezia gerardii.A new sequenced species(Graphis supracola),one new host(Aplosporella prunicola)and three new geographical records(Golovinomyces monardae,Paradictyoarthrinium diffractum and Prosthemium betulinum),are reported. | Hai-Sheng Yuan Xu Lu Yu-Cheng Dai Kevin D.Hyde Yu-He Kan Ivana Kušan Shuang-Hui He Ning-Guo Liu V.Venkateswara Sarma Chang-Lin Zhao Bao-Kai Cui Nousheen Yousaf Guangyu Sun Shu-Yan Liu Fang Wu Chuan-Gen Lin Monika C.Dayarathne Tatiana Baptista Gibertoni Lucas B.Conceição Roberto Garibay-Orijel Margarita Villegas-Ríos Rodolfo Salas-Lizana Tie-Zheng Wei Jun-Zhi Qiu Ze-Fen Yu Rungtiwa Phookamsak Ming Zeng Soumitra Paloi Dan-Feng Bao Pranami DAbeywickrama De-Ping Wei Jing Yang Ishara S.Manawasinghe Dulanjalee Harishchandra Rashika S.Brahmanage Nimali Ide Silva Danushka S.Tennakoon Anuruddha Karunarathna Yusufjon Gafforov Dhandevi Pem Sheng-Nan Zhang AndréL.C.Mde Azevedo Santiago Jadson Diogo Pereira Bezerra Bálint Dima Krishnendu Acharya Julieta Alvarez-Manjarrez Ali H.Bahkali Vinod K.Bhatt Tor Erik Brandrud Timur S.Bulgakov E.Camporesi Ting Cao Yu-Xi Chen Yuan-Yuan Chen Bandarupalli Devadatha Abdallah M.Elgorban Long-Fei Fan Xing Du Liu Gao Camila Melo Gonçalves Luis F.P.Gusmão Naruemon Huanraluek Margita Jadan Ruvishika S.Jayawardena Abdul Nasir Khalid Ewald Langer Diogo X.Lima Nelson Correia de Lima-Júnior Carla Rejane Sousa de Lira Jian-Kui(Jack)Liu Shun Liu Saisamorn Lumyong Zong-Long Luo Neven Matočec M.Niranjan JoséRibamar Costa Oliveira-Filho Viktor Papp Eduardo Pérez-Pazos Alan J.L.Phillips Peng-Lei Qiu Yihua Ren Rafael F.Castañeda Ruiz Kamal C.Semwal Karl Soop Carlos A.Fde Souza Cristina Maria Souza-Motta Li-Hua Sun Meng-Le Xie Yi-Jian Yao Qi Zhao Li-Wei Zhou | 2020 | Fungal Diversity2020，，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员